JP6074435B2 - 変異ctla4遺伝子移入t細胞及びこれを含む抗がん免疫治療用組成物 - Google Patents
変異ctla4遺伝子移入t細胞及びこれを含む抗がん免疫治療用組成物 Download PDFInfo
- Publication number
- JP6074435B2 JP6074435B2 JP2014538714A JP2014538714A JP6074435B2 JP 6074435 B2 JP6074435 B2 JP 6074435B2 JP 2014538714 A JP2014538714 A JP 2014538714A JP 2014538714 A JP2014538714 A JP 2014538714A JP 6074435 B2 JP6074435 B2 JP 6074435B2
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- ctla4
- cancer
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims description 286
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 title claims description 75
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 title claims description 72
- 230000001093 anti-cancer Effects 0.000 title description 25
- 239000000203 mixture Substances 0.000 title description 10
- 230000001024 immunotherapeutic effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims description 134
- 201000011510 cancer Diseases 0.000 claims description 93
- 108090000623 proteins and genes Proteins 0.000 claims description 88
- 239000000427 antigen Substances 0.000 claims description 61
- 108091007433 antigens Proteins 0.000 claims description 61
- 102000036639 antigens Human genes 0.000 claims description 61
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 52
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 52
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 39
- 230000003834 intracellular effect Effects 0.000 claims description 35
- 108020001507 fusion proteins Proteins 0.000 claims description 32
- 102000037865 fusion proteins Human genes 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 26
- 230000006044 T cell activation Effects 0.000 claims description 17
- 108020003175 receptors Proteins 0.000 claims description 15
- 102000005962 receptors Human genes 0.000 claims description 14
- 230000004068 intracellular signaling Effects 0.000 claims description 11
- 230000003612 virological effect Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 9
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 210000000170 cell membrane Anatomy 0.000 claims description 5
- 230000006058 immune tolerance Effects 0.000 claims description 5
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims description 4
- 102000018697 Membrane Proteins Human genes 0.000 claims description 4
- 108010052285 Membrane Proteins Proteins 0.000 claims description 4
- 101800001271 Surface protein Proteins 0.000 claims description 4
- 102000003425 Tyrosinase Human genes 0.000 claims description 4
- 108060008724 Tyrosinase Proteins 0.000 claims description 4
- 230000001131 transforming effect Effects 0.000 claims description 4
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 3
- 239000012830 cancer therapeutic Substances 0.000 claims description 3
- 230000024664 tolerance induction Effects 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 2
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 102000006815 folate receptor Human genes 0.000 claims description 2
- 108020005243 folate receptor Proteins 0.000 claims description 2
- 238000012737 microarray-based gene expression Methods 0.000 claims description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 1
- 102000013816 Cytotoxic T-lymphocyte antigen 4 Human genes 0.000 claims 1
- 230000031146 intracellular signal transduction Effects 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 80
- 230000000694 effects Effects 0.000 description 43
- 241000699670 Mus sp. Species 0.000 description 29
- 102100037850 Interferon gamma Human genes 0.000 description 20
- 108010074328 Interferon-gamma Proteins 0.000 description 20
- 230000001965 increasing effect Effects 0.000 description 20
- 230000000259 anti-tumor effect Effects 0.000 description 18
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 17
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 16
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 16
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 15
- 238000009169 immunotherapy Methods 0.000 description 14
- 239000003446 ligand Substances 0.000 description 14
- 230000009466 transformation Effects 0.000 description 14
- 241001430294 unidentified retrovirus Species 0.000 description 14
- 108060001084 Luciferase Proteins 0.000 description 13
- 239000005089 Luciferase Substances 0.000 description 13
- 230000004913 activation Effects 0.000 description 12
- 238000002659 cell therapy Methods 0.000 description 12
- 108010002350 Interleukin-2 Proteins 0.000 description 11
- 102000000588 Interleukin-2 Human genes 0.000 description 11
- 108010058846 Ovalbumin Proteins 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 229940092253 ovalbumin Drugs 0.000 description 11
- 108091008874 T cell receptors Proteins 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 230000001177 retroviral effect Effects 0.000 description 9
- 230000019491 signal transduction Effects 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 239000005090 green fluorescent protein Substances 0.000 description 7
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 102000008096 B7-H1 Antigen Human genes 0.000 description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 241000699800 Cricetinae Species 0.000 description 4
- 208000001382 Experimental Melanoma Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000003127 anti-melanomic effect Effects 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- -1 41BBL Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 102000009438 IgE Receptors Human genes 0.000 description 2
- 108010073816 IgE Receptors Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000011224 anti-cancer immunotherapy Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000005880 cancer cell killing Effects 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100222220 Mus musculus Ctla4 gene Proteins 0.000 description 1
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229940124060 PD-1 antagonist Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001183 RAG-1 Human genes 0.000 description 1
- 108060006897 RAG1 Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 101150056647 TNFRSF4 gene Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005904 anticancer immunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000009172 cell transfer therapy Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
- 208000037516 chromosome inversion disease Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- 230000007896 negative regulation of T cell activation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Description
「膜貫通ドメイン(transmembrane domain)」は、CTLA4、CD28などにおいて、細胞膜に位置するドメインを意味し、
「細胞内ドメイン(intracellular domain)」は、細胞の内部に位置し、細胞外ドメインとリガンドが結合されて伝達される信号を細胞内に伝達するドメインを意味する。
Pmel−1、OT−I、B6とThy1.1+コンジェニックB6マウスは、ジャクソン研究所から入手した。RAG1−/−背景を有するOT−IIマウスは、タコニックから入手した。形質転換マウスは全てB6背景を有する。マウスは、国立がんセンター内の特定の病原体がない施設において飼育され、国立センターの実験動物管理および使用委員会のガイドラインを遵守した。
CTLA4−CD28キメラを製作するために、マウス由来CTLA4の細胞外ドメインと膜貫通ドメインをコードするヌクレオチド配列(配列番号9)とマウスCD28の細胞内ドメインをコードするヌクレオチド配列(配列番号10)はマウスCTLA4およびCD28cDNAを含むプラスミドから重合酵素連鎖反応(PCR:polymerase chain reaction)によって増幅して得た。
ジャーカットT細胞(1×107)は、レトロウィルス発現プラスミド、RE/APルシフェラーゼプラスミド(カリフォルニア大学のArthur Weiss教授提供)および標準化のためのpRL−TKレニラルシフェラーゼプラスミド(プロメガ社製)と混合した。
リポフェクタミン2000(インビトロジェン社製)を用いてレトロウィルス性プラスミドとVSV−GcDNAをコードするプラスミドであるpMD.GをフェニックスGP細胞株に形質転換した。48時間後にVSV−G偽型レトロウィルスを含む上澄み液を回収した。フェニックスエコー細胞株はレトロウィルスを含む上澄み液を用いて一晩中形質転換した。
細胞選別によって分離されたGFP−陽性細胞(2×104/well)は、48時間照射された脾臓細胞(2×105/well)の存在下で様々な濃度の抗CD3抗体または抗原ペプチドによって刺激された。
B6マウスに0日目にE.G7細胞(1〜2×106)またはB16細胞(1×105)を皮下注射した。レトロウィルスに形質転換されたT細胞は7日目にマウスに移入された。B16黒色腫モデルの場合、T細胞が移入される日に、マウスを骨髄非形成全身照射(nonmyeloablative total body irradiation、TBI)(4Gy)してリンパ球枯渇させた。
マウス由来CTLA4(配列番号2参照)の細胞内部抑制信号伝達ドメインが除去されたCTLA4突然変異体であるCTLA4デコイ受容体およびCTLA4−CD28キメラタンパク質(配列番号6参照)を発現するレトロウィルス性遺伝子構造体を図2(b)に示すように製作した。
腫瘍抗原に特異的なT細胞のCTLA4−CD28キメラ遺伝子の発現によって、T細胞の抗腫瘍活性が強化されるか否かを確認するために、Pmel−1と呼ばれる黒色腫抗原特異的なTCR形質転換マウスから由来したCD8 T細胞(Pmel−1 T細胞)をCTLA4−CD28キメラ遺伝子を含むレトロウィルスを用いて形質転換させた。Pmel−1 T細胞は、同系B16黒色腫細胞の表面に発現される腫瘍抗原であるgp100を特異的に認識する。
実験例1と実験例2の違いは、実験例1の場合には正常マウスから分離されたT細胞はCD4およびCD8 T細胞が混合されたものであるのに対し、Pmel−1 T細胞はCD8 T細胞のみが存在するという点である。このため、CTLA4−CD28キメラ遺伝子の形質転換によってCD4およびCD8 T細胞の腫瘍抗原特異的な反応が互いに異なるように調節されるか否かを確認する必要がある。
CD4 T細胞がCD8 T細胞の抗腫瘍効果に必要であるということはよく知られている。このため、腫瘍抗原に対する強化されたCD4の反応は、腫瘍抗原特異的なCD8 T細胞の抗腫瘍効果を倍加させることができるものと認められる。
実験例4におけるモデルは、OVAという人為的な腫瘍抗原に対して抗腫瘍効果を試験したものであるため、CTLA4−CD28キメラ遺伝子に形質転換されたCD4およびCD8 T細胞を用いて実際に腫瘍抗原を含有するモデルにおける抗腫瘍効果を試験することが必要である。
しかしながら、B16腫瘍は良好ではない免疫原性を有しており、T細胞免疫療法に抵抗性を有していることが知られており、本発明におけるCTLA4−CD28キメラ遺伝子に形質転換されたPmel−1 T細胞を用いた場合にも抗腫瘍効果の向上は顕著ではなかったが(実験例2参照)、多クローンCD4 T細胞の添加を通じてPmel−1 T細胞を用いたT細胞免疫療法が効果があるかもしれないという報告がある。
Claims (13)
- 配列番号5〜7のいずれかのアミノ酸配列を有する融合タンパク質を含む癌治療のための免疫寛容を抑制する遺伝子組み換えT細胞であり、
前記融合タンパク質は、細胞内信号伝達ドメインを除去したT細胞表面免疫寛容誘導受容体である細胞傷害性Tリンパ球関連タンパク質4(CTLA4:Cytotoxic T−Lymphocyte−Associated Protein 4またはT−Lymphocyte Antigen 4)と、T細胞活性化表面タンパク質CD28の細胞内信号伝達ドメインとを含み、前記細胞内信号伝達ドメインは、CTLA4またはCD28の膜貫通ドメインによってCTLA4に融合されることを特徴とするT細胞。 - CTLA4は、配列番号1のヒト由来のアミノ酸配列または配列番号2のマウス由来のアミノ酸配列を有することを特徴とする請求項1に記載のT細胞。
- CD28は、配列番号3のヒト由来のアミノ酸配列または配列番号4のマウス由来のアミノ酸配列を有することを特徴とする請求項1に記載のT細胞。
- 配列番号1または配列番号2のアミノ酸配列において、CTLA4の細胞外ドメインは1〜161番目までのアミノ酸配列であり、CTLA4の細胞膜ドメインは162〜189番目までのアミノ酸配列であり、CTLA4の細胞内信号伝達ドメインは190〜223番目までのアミノ酸配列を有することを特徴とする請求項2に記載のT細胞。
- CD28の細胞外ドメインは、配列番号3の1〜152番目までのアミノ酸配列であるか、あるいは、配列番号4の1〜150番目までのアミノ酸配列であり、CD28の細胞膜ドメインは、配列番号3の153〜178番目までのアミノ酸配列であるか、あるいは、配列番号4の151〜176番目までのアミノ酸配列であり、CD28の細胞内信号伝達ドメインは、配列番号3の179〜220番目までのアミノ酸配列であるか、あるいは、配列番号4の177〜218番目までのアミノ酸配列を有することを特徴とする請求項3に記載のT細胞。
- 配列番号5のアミノ酸配列または配列番号6のアミノ酸配列を有する前記融合タンパク質は、CTLA4の細胞外ドメイン、CTLA4の膜貫通ドメイン、及びCD28の細胞内信号伝達ドメインを含むことを特徴とする請求項1に記載のT細胞。
- 配列番号7のアミノ酸配列を有する前記融合タンパク質は、CTLA4の細胞外ドメイン、CD28の細胞膜ドメイン、及びCD28の細胞内信号伝達ドメインを含むことを特徴とする請求項1に記載のT細胞。
- 前記T細胞は、がん抗原に特異的なT細胞であることを特徴とする請求項1に記載のT細胞。
- 前記がん抗原に特異的なT細胞は、がん抗原に特異的なCD4 T細胞、がん抗原に特異的なCD8 T細胞、またはがん抗原に特異的なCD4 T細胞およびがん抗原に特異的なCD8 T細胞の組み合わせであることを特徴とする請求項8に記載の形質転換されたT細胞。
- 前記がん抗原に特異的なT細胞は、患者のがん組織から分離したT細胞、がん抗原特異的に認知する受容体遺伝子に形質転換されたT細胞およびキメラ抗原受容体(CAR)遺伝子に形質転換されたT細胞よりなる群から選ばれるいずれか一種であることを特徴とする請求項8に記載のT細胞。
- がん抗原は、MUC1、CD19、HER2、EGFR、CD20、CEA、PSMA、GD2、葉酸受容体、IL−13Rα2、Lewis−Y抗原、NY−ESO−1、MART−1、gp100、チロシナーゼ、チロシナーゼ関連タンパク質、MAGEおよびWT−1よりなる群から選ばれるいずれか一種であることを特徴とする請求項8に記載のT細胞。
- 請求項1から請求項11のうちのいずれか1項に記載のT細胞を含むがん治療用薬学的組成物。
- 請求項1に記載のCTLA4の細胞外ドメイン、CTLA4の膜貫通ドメイン、及びCD28の細胞内信号伝達ドメインよりなる融合タンパク質を含むT細胞の製造方法であって、
(a)CTLA4の細胞外ドメインとCTLA4の膜貫通ドメインをコードする配列番号9の配列を有するヌクレオチド、及びCD28の細胞内信号伝達ドメインをコードする配列番号10の配列を有するヌクレオチドを結合させることにより、融合タンパク質をコードするポリヌクレオチドを製造する工程と、
(b)前記ポリヌクレオチドを含むウイルスまたは非ウイルス性担体を構成する工程と、
(c)前記ウイルスまたは非ウイルス性担体を用いてがん抗原に特異的なT細胞を形質転換させるステップを含むT細胞の製造方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110109729 | 2011-10-26 | ||
KR10-2011-0109729 | 2011-10-26 | ||
KR1020120119603A KR101471647B1 (ko) | 2011-10-26 | 2012-10-26 | 변이 ctla4 유전자 이입 t 세포 및 이를 포함하는 항암 면역치료용 조성물 |
KR10-2012-0119603 | 2012-10-26 | ||
PCT/KR2012/008878 WO2013062365A2 (ko) | 2011-10-26 | 2012-10-26 | 변이 ctla4 유전자 이입 t 세포 및 이를 포함하는 항암 면역치료용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014532642A JP2014532642A (ja) | 2014-12-08 |
JP6074435B2 true JP6074435B2 (ja) | 2017-02-01 |
Family
ID=48657742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014538714A Active JP6074435B2 (ja) | 2011-10-26 | 2012-10-26 | 変異ctla4遺伝子移入t細胞及びこれを含む抗がん免疫治療用組成物 |
Country Status (3)
Country | Link |
---|---|
US (1) | US9688740B2 (ja) |
JP (1) | JP6074435B2 (ja) |
KR (1) | KR101471647B1 (ja) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9844582B2 (en) | 2012-05-22 | 2017-12-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
DK2958943T3 (da) | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
WO2014201378A1 (en) * | 2013-06-13 | 2014-12-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy |
CN106687483B (zh) | 2014-07-21 | 2020-12-04 | 诺华股份有限公司 | 使用人源化抗-bcma嵌合抗原受体治疗癌症 |
AR101829A1 (es) | 2014-07-21 | 2017-01-18 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 |
WO2016138846A1 (en) * | 2015-03-02 | 2016-09-09 | Shanghai Sidansai Biotechnology Co., Ltd | Reducing immune tolerance induced by pd‐l1 |
US20180044404A1 (en) * | 2015-03-05 | 2018-02-15 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
CN115925971A (zh) * | 2015-06-19 | 2023-04-07 | 塞巴斯蒂安·科博尔德 | Pd-1-cd28融合蛋白及其在医学中的用途 |
JP2018520679A (ja) * | 2015-06-29 | 2018-08-02 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 免疫チェックポイントキメラ抗原受容体療法 |
WO2017023803A1 (en) | 2015-07-31 | 2017-02-09 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
JP7250519B2 (ja) * | 2016-03-23 | 2023-04-03 | ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト (ゲーエムベーハー) | Pd-1及び4-1bbの融合タンパク質 |
US11261233B2 (en) * | 2016-09-19 | 2022-03-01 | OncoC4, Inc. | CD80 and CD86 binding protein compositions and uses thereof |
CN110520530A (zh) | 2016-10-18 | 2019-11-29 | 明尼苏达大学董事会 | 肿瘤浸润性淋巴细胞和治疗方法 |
CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
AU2017382902A1 (en) * | 2016-12-21 | 2019-07-18 | TCR2 Therapeutics Inc. | Engineered T cells for the treatment of cancer |
CN110612119A (zh) | 2017-02-07 | 2019-12-24 | 西雅图儿童医院(Dba西雅图儿童研究所) | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
EP3589295A4 (en) | 2017-02-28 | 2020-11-04 | Endocyte, Inc. | COMPOSITIONS AND METHODS OF T CAR LYMPHOCYTE THERAPY |
MX2019010812A (es) | 2017-03-17 | 2019-12-11 | Hutchinson Fred Cancer Res | Proteinas de fusion inmunomoduladoras y sus usos. |
WO2018195339A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
WO2019006418A2 (en) | 2017-06-30 | 2019-01-03 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
RU2020113680A (ru) | 2017-09-19 | 2021-10-20 | Массачусетс Инститьют Оф Текнолоджи | Композиции для т-клеточной терапии с химерным антигенным рецептором и их применения |
US20220347244A1 (en) * | 2018-01-19 | 2022-11-03 | Kolon Life Science, Inc. | Recombinant vaccinia virus and pharmaceutical composition comprising same |
WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
BR112020025048A2 (pt) | 2018-06-13 | 2021-04-06 | Novartis Ag | Receptores de antígeno quimérico de bcma e usos dos mesmos |
EP3856763A1 (en) | 2018-09-28 | 2021-08-04 | Massachusetts Institute of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
US11642409B2 (en) | 2019-06-26 | 2023-05-09 | Massachusetts Insttute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
WO2021183675A2 (en) | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | Methods for generating engineered memory-like nk cells and compositions thereof |
EP4118112A1 (en) | 2020-03-10 | 2023-01-18 | Massachusetts Institute of Technology | Compositions and methods for immunotherapy of npm1c-positive cancer |
US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
US20210338833A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
CN115969971B (zh) * | 2022-11-24 | 2023-08-18 | 珠海恩科生物科技有限公司 | 组合物在制备治疗肿瘤的药物中的应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2003455C (en) * | 1988-11-23 | 2000-02-22 | Craig B. Thompson | Immunotherapy involving cd28 stimulation |
US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
US5858776A (en) | 1993-11-03 | 1999-01-12 | Repligen Corporation | Tumor cells with increased immunogenicity and uses therefor |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
WO2003008583A2 (en) * | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
US7465446B2 (en) | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
WO2005014612A1 (en) * | 2003-07-09 | 2005-02-17 | The Brigham And Women's Hospital, Inc. | Novel splice variant of ctla-4 |
GB0903325D0 (en) * | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
AU2012290342A1 (en) | 2011-07-29 | 2014-01-30 | The Trustees Of The University Of Pennsylvania | Switch costimulatory receptors |
-
2012
- 2012-10-26 JP JP2014538714A patent/JP6074435B2/ja active Active
- 2012-10-26 US US14/354,562 patent/US9688740B2/en active Active
- 2012-10-26 KR KR1020120119603A patent/KR101471647B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR101471647B1 (ko) | 2014-12-11 |
JP2014532642A (ja) | 2014-12-08 |
KR20130045824A (ko) | 2013-05-06 |
US9688740B2 (en) | 2017-06-27 |
US20140242049A1 (en) | 2014-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6074435B2 (ja) | 変異ctla4遺伝子移入t細胞及びこれを含む抗がん免疫治療用組成物 | |
Shin et al. | Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models | |
Patel et al. | Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma | |
Hillerdal et al. | Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer | |
Zhou et al. | Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia | |
JP2022188225A (ja) | 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ | |
JP6489353B2 (ja) | 腫瘍療法のためのil−12とt細胞阻害分子遮断薬とを含む医薬組成物 | |
WO2017219936A1 (zh) | 一种高效稳定表达激活型抗体的car-t细胞及其用途 | |
US8475785B2 (en) | Allogeneic cancer cell-based immunotherapy | |
Jackson et al. | Targeting CD8+ T-cell tolerance for cancer immunotherapy | |
JP2021008481A (ja) | 悪性腫瘍の治療に対する方法 | |
US20190218260A1 (en) | Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens | |
WO2021232200A1 (en) | Il-12 armored immune cell therapy and uses thereof | |
Cannon et al. | Cellular immunotherapy for ovarian cancer | |
Fujii et al. | Cancer immunotherapy using artificial adjuvant vector cells to deliver NY‐ESO‐1 antigen to dendritic cells in situ | |
Saha et al. | Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen | |
WO2013062365A2 (ko) | 변이 ctla4 유전자 이입 t 세포 및 이를 포함하는 항암 면역치료용 조성물 | |
Tu et al. | Incorporation of a TGF-β2-inhibiting oligodeoxynucleotide molecular adjuvant into a tumor cell lysate vaccine to enhance antiglioma immunity in mice | |
WO2024060140A1 (zh) | EGFRvIII嵌合抗原受体及其用途 | |
US20210401893A1 (en) | T cell expressing an fc gamma receptor and methods of use thereof | |
Fallatah | Combination of immune stimulatory strategies to promote anti-tumour immunity | |
Opel | T cell mediated combination immunotherapy | |
Monroy-Garcial’zf et al. | Cancer immunology and novel strategies for immunotherapy | |
Pardee | Cancer immunotherapy targeting T cell costimulatory molecules | |
Mansoor et al. | Genetically Modified T Cell Therapy Optimisation of the Chimeric T Cell Receptor for Cancer Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150616 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151016 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160301 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160530 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160705 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161115 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161128 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170106 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6074435 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |